Cannabinoids in progressive inflammatory brain disease (CUPID)

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN62942668

Enrollment

500

Registered

2005-06-21

Start date

2005-07-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

Participants are randomly allocated to one of two groups in a 2:1 ratio (intervention:control) Intervention group: Participants take a maximum of 28mg/day oral tetrahydrocannabinol (THC) for six mont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary/secondary progressive multiple sclerosis 2. Worsening disability 3. Age 18-65 4. EDSS score 4 to 6.5

Exclusion criteria

Exclusion criteria: 1. Immunodulation or immunosuppressive therapy 2. Steroids or cannabinoids recently 3. Psychotic illness 4. Cognitive impairment 5. Pregnancy

Design outcomes

Primary

Measure	Time frame
Added 17/07/09: 1. Physician-based EDSS: time to EDSS progression of at least one point from a baseline EDSS of 4.0, 4.5 or 5.0 or at least 0.5 points from a baseline EDSS =5.5. Once identified, deterioration must be confirmed at the next scheduled six monthly visit. 2. Change in Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29v2) 20-point physical subscale (MSIS-29phys) score	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 18, 2026